

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTALAB1643

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\*\*\*\*\* Welcome to STN International \*\*\*\*\*

NEWS 1 Web Page for STN Seminar Schedule - N. America  
NEWS 2 DEC 01 ChemPort single article sales feature unavailable  
NEWS 3 APR 03 CAS coverage of exemplified prophetic substances  
enhanced  
NEWS 4 APR 07 STN is raising the limits on saved answers  
NEWS 5 APR 24 CA/CAplus now has more comprehensive patent assignee  
information  
NEWS 6 APR 26 USPATFULL and USPAT2 enhanced with patent  
assignment/reassignment information  
NEWS 7 APR 28 CAS patent authority coverage expanded  
NEWS 8 APR 28 ENCOMPLIT/ENCOMPLIT2 search fields enhanced  
NEWS 9 APR 28 Limits doubled for structure searching in CAS  
REGISTRY  
NEWS 10 MAY 08 STN Express, Version 8.4, now available  
NEWS 11 MAY 11 STN on the Web enhanced  
NEWS 12 MAY 11 BEILSTEIN substance information now available on  
STN Easy  
NEWS 13 MAY 14 DGENE, PCTGEN and USGENE enhanced with increased  
limits for exact sequence match searches and  
introduction of free HIT display format  
NEWS 14 MAY 15 INPADOCDB and INPAFAMDB enhanced with Chinese legal  
status data  
NEWS 15 MAY 28 CAS databases on STN enhanced with NANO super role in  
records back to 1992  
NEWS 16 JUN 01 CAS REGISTRY Source of Registration (SR) searching  
enhanced on STN

NEWS EXPRESS MAY 26 09 CURRENT WINDOWS VERSION IS V8.4,  
AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.

NEWS HOURS STN Operating Hours Plus Help Desk Availability

## NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

\*\*\*\*\* STN Columbus \*\*\*\*\*

FILE 'HOME' ENTERED AT 15:11:08 ON 17 JUN 2009

=> file caplus

COST IN U.S. DOLLARS	ENTRY	SINCE FILE SESSION	TOTAL
FULL ESTIMATED COST		0.22	0.22

FILE 'CAPLUS' ENTERED AT 15:11:26 ON 17 JUN 2009

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 17 Jun 2009 VOL 150 ISS 25

FILE LAST UPDATED: 16 Jun 2009 (20090616/ED)

REVISED CLASS FIELDS (/NCL) LAST RELOADED: Apr 2009

USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2009

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s GC33 and (GPC-3 or glypican 3)

7 GC33  
15004 GPC  
85 GPCS  
15053 GPC  
(GPC OR GPCS)  
7644384 3  
73 GPC-3  
(GPC(W)3)  
716 GLYPICAN  
345 GLYPICANS  
776 GLYPICAN  
(GLYPICAN OR GLYPICANS)  
7644384 3  
299 GLYPICAN 3  
(GLYPICAN(W)3)

L1 3 GC33 AND (GPC-3 OR GLYPICAN 3)

=> duplicate remove

ENTER L# LIST OR (END):L1

PROCESSING COMPLETED FOR L1

L2 3 DUPLICATE REMOVE L1 (0 DUPLICATES REMOVED)

=> d L2 bib abs 1-3

L2 ANSWER 1 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2008:1471243 CAPLUS

DN 150:53942

TI Anti-glypican 3 antibodies cause ADCC against human  
hepatocellular carcinoma cells

AU Nakano, Kiyotaka; Orita, Tetsuro; Nezu, Junichi; Yoshino, Takeshi;  
Ohizumi, Iwao; Sugimoto, Masamichi; Furugaki, Koh; Kinoshita, Yasuko;  
Ishiguro, Takahiro; Hamakubo, Takao; Kodama, Tatsuhiko; Aburatani,  
Hiroyuki; Yamada-Okabe, Hisafumi; Tsuchiya, Masayuki

CS Research Laboratories, Chugai Pharmaceutical Co. Ltd., 1-135 Komakado,  
Gotemba, Shizuoka, 412-8513, Japan

SO Biochemical and Biophysical Research Communications (2009), 378(2),  
279-284

CODEN: BBRCA9; ISSN: 0006-291X

PB Elsevier B.V.

DT Journal

LA English

AB Glypican 3 (GPC3), a GPI-anchored heparan sulfate proteoglycan, is expressed in the majority of hepatocellular carcinoma (HCC) tissues. Using MRL/lpr mice, the authors successfully generated a series of anti-GPC3 monoclonal antibodies (mAbs). GPC3 was partially cleaved between Arg358 and Ser359, generating a C-terminal 30-kDa fragment and an N-terminal 40-kDa fragment. All mAbs that induced antibody-dependent cellular cytotoxicity (ADCC) and/or complement-dependent cytotoxicity (CDC) against cells expressing GPC3 recognized the 30-kDa fragment, indicating that the C-terminal region of GPC3 serves as an epitope for mAb with ADCC and/or CDC inducing activities. Chimeric mAbs with Fc replaced by human IgG1 were created from GC33, one of the mAbs that reacted with the C-terminal 30-kDa fragment. Chimeric GC33 induced not only ADCC against GPC3-pos. human HCC cells but also was efficacious against the Huh-7 human HCC xenograft. Thus, mAbs against the C-terminal 30-kDa fragment such as GC33 are useful in therapy targeting HCC.

RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2008:1433769 CAPLUS

DN 150:18894

TI Anti-Glypican 3 Antibody as a Potential Antitumor Agent for Human Liver Cancer

AU Ishiguro, Takahiro; Sugimoto, Masamichi; Kinoshita, Yasuko; Miyazaki, Yoko; Nakano, Kiyotaka; Tsunoda, Hiroyuki; Sugo, Izumi; Ohizumi, Iwao; Aburatani, Hiroyuki; Hamakubo, Takao; Kodama, Tatsuhiko; Tsuchiya, Masayuki; Yamada-Okabe, Hisafumi

CS Pharmaceutical Research Department, Chugai Pharmaceutical Co. Ltd., Kanagawa, 412-8513, Japan

SO Cancer Research (2008), 68(23), 9832-9838

CODEN: CNREA8; ISSN: 0008-5472

PB American Association for Cancer Research

DT Journal

LA English

AB Human glypican 3 (GPC3) is preferentially expressed in the tumor tissues of liver cancer patients. In this study, we obtained a monoclonal antibody (mAb) against the COOH-terminal part of GPC3, which induced antibody-dependent cellular cytotoxicity (ADCC). The mAb, designated GC33, exhibited marked tumor growth inhibition of s.c. transplanted Hep G2 and HuH-7 xenografts that expressed GPC3 but did not inhibit growth of the SK-HEP-1 that was neg. for GPC3. GC33 was efficacious even in an orthotopic model; it markedly reduced the blood

.alpha.-fetoprotein levels of mice intrahepatically transplanted with Hep G2 cells. Humanized GC33 (hGC33) was as efficacious as GC33 against the Hep G2 xenograft, but hGC33 lacking carbohydrate moieties caused neither ADCC nor tumor growth inhibition. Depletion of CD56+ cells from human peripheral blood mononuclear cells markedly abrogated the ADCC caused by hGC33. The results show that the antitumor activity of hGC33 is mainly attributable to ADCC, and in human, natural killer cell-mediated ADCC is one possible mechanism of the antitumor effects by GC33. hGC33 will provide a novel treatment option for liver cancer patients with GPC3-pos. tumors.

RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L2 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2009 ACS on STN

AN 2006:193650 CAPLUS

DN 144:267250

TI Anti-glypican 3 antibody for preventing liver tumor recurrence

IN Kinoshita, Yasuko; Sugimoto, Masamichi; Okabe, Hisafumi

PA Chugai Seiyaku Kabushiki Kaisha, Japan

SO PCT Int. Appl., 33 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
PI WO 2006022407	A1	20060302	WO 2005-JP15607	20050823
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
EP 1800693	A1	20070627	EP 2005-780979	20050823
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN 101014367	A	20070808	CN 2005-80028610	20050823
KR 2007050963	A	20070516	KR 2007-705914	20070314

US 20070269444    A1   20071122   US 2007-574091    20070611  
PRAI JP 2004-244273    A   20040824  
JP 2005-90945    A   20050328  
WO 2005-JP15607    W   20050823

AB   Described is an anti-glypican 3 antibody administered  
after the removal of cancer, esp. liver tumor, to prevent tumor  
recurrence. This anticancer agent is preferably employed in the case  
where glypican 3 is expressed in the removed liver  
cancer cells. Anti-glypican 3 antibody is useful in  
monitoring tumor cells in patients after removal of the tumor. Anti-  
glypican 3 antibody GC33 decreased the concn.  
of serum AFP (.alpha.-fetoprotein) in mouse liver tumor models induced by  
injection of HepG2 cells into membrana dermalis of livers.

RE.CNT 5    THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS  
RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT